We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
+9.26%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$72M
(-20%)
Cap. Flow
-$84.2M
Cap. Flow
% of AUM
-28.48%
Top 10 Holdings %
Top 10 Hldgs %
6.88%
Holding
509
New
39
Increased
197
Reduced
202
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Constellation Energy
CEG
|
+$1.64M |
| 2 |
Veeva Systems
VEEV
|
+$1.51M |
| 3 |
Cisco
CSCO
|
+$1.5M |
| 4 |
Fox Class A
FOXA
|
+$1.48M |
| 5 |
DoorDash
DASH
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19M |
| 4 |
SMC
Summit Midstream
SMC
|
+$3.67M |
| 5 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$2.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.24% |
| 2 | Healthcare | 17.43% |
| 3 | Technology | 12.41% |
| 4 | Industrials | 9.1% |
| 5 | Consumer Discretionary | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Cartesian Therapeutics
RNAC
$268M
| $95.4K | 0.03% |
9,183
+1,023
| +13% | +$10.9K |
|
352
Tango Therapeutics
TNGX
$4.41B
| $95.3K | 0.03% |
18,620
-38,979
| -68% | -$96.4K |
|
353
Savara
SVRA
$1.19B
| $94.9K | 0.03% |
41,607
-7,399
| -15% | -$20.1K |
|
354
Disc Medicine
IRON
$2.97B
| $94.5K | 0.03% |
1,784
-772
| -30% | -$36.3K |
|
355
Immunovant
IMVT
$8.25B
| $94.4K | 0.03% |
5,899
-54
| -0.9% | -$817 |
|
356
Relay Therapeutics
RLAY
$4.33B
| $94.3K | 0.03% |
27,256
-7,089
| -21% | -$21.1K |
|
357
Celldex Therapeutics
CLDX
$3.28B
| $94K | 0.03% |
4,621
-1,587
| -26% | -$30.9K |
|
|
ITOS
358
DELISTED
iTeos Therapeutics
ITOS
| $93.9K | 0.03% |
9,422
-11,241
| -54% | -$90.6K |
|
|
AKRO
359
DELISTED
Akero Therapeutics
AKRO
| $93.7K | 0.03% |
1,756
-3,898
| -69% | -$177K |
|
360
Cytokinetics
CYTK
$10.4B
| $93.6K | 0.03% |
2,832
-438
| -13% | -$15.2K |
|
361
Cogent Biosciences
COGT
$7.24B
| $93.5K | 0.03% |
13,024
-6,663
| -34% | -$36.9K |
|
|
LENZ
362
LENZ Therapeutics
LENZ
$168M
| $93.2K | 0.03% |
3,179
-2,155
| -40% | -$58.6K |
|
|
ACLX
363
DELISTED
Arcellx
ACLX
| $93.1K | 0.03% |
1,414
-554
| -28% | -$34.5K |
|
364
Protagonist Therapeutics
PTGX
$9.44B
| $92.3K | 0.03% |
1,670
-2,395
| -59% | -$115K |
|
365
CG Oncology
CGON
$6.66B
| $92.2K | 0.03% |
3,548
-2,138
| -38% | -$51.5K |
|
|
NUVL
366
DELISTED
Nuvalent
NUVL
| $92.1K | 0.03% |
1,207
-683
| -36% | -$50K |
|
367
Keros Therapeutics
KROS
$221M
| $92K | 0.03% |
6,894
-2,013
| -23% | -$27.2K |
|
368
Recursion Pharmaceuticals
RXRX
$1.73B
| $92K | 0.03% |
18,188
-5,330
| -23% | -$26.2K |
|
369
Beam Therapeutics
BEAM
$2.84B
| $91.7K | 0.03% |
5,392
-464
| -8% | -$8.08K |
|
|
MREO
370
Mereo BioPharma
MREO
$47.3M
| $91.7K | 0.03% |
33,825
-10,182
| -23% | -$24.6K |
|
371
Arrowhead Research
ARWR
$12.4B
| $91.6K | 0.03% |
5,797
-1,618
| -22% | -$23.2K |
|
372
Arvinas
ARVN
$572M
| $91.4K | 0.03% |
12,422
+4,104
| +49% | +$30.2K |
|
|
CVAC
373
DELISTED
CureVac
CVAC
| $91.2K | 0.03% |
16,792
-34,504
| -67% | -$137K |
|
374
Dianthus Therapeutics
DNTH
$6.09B
| $90.8K | 0.03% |
4,875
-2,111
| -30% | -$39.6K |
|
375
Vir Biotechnology
VIR
$1.49B
| $90.8K | 0.03% |
18,014
-4,079
| -18% | -$21.9K |
|
Similar funds
RC
MS
WI
HS
SIAG
WTFG
A6
ACM
Virtus Investment Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, Virtus Investment Advisers held 509 positions worth $296M, down 20% from $368M the previous quarter. Its ten largest holdings account for 6.9% of the portfolio.
Virtus Investment Advisers withdrew a net $84.2M in Q2 2025, closing 70 positions and reducing 202 holdings. Its most notable exit was Virtus Newfleet ABS/MBS ETF, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Virtus Investment Advisers opened a new position in Constellation Energy worth $2.01M.
- Virtus Investment Advisers's largest Q2 2025 buy was Constellation Energy: 6,213 shares worth $2.01M.
- Virtus Investment Advisers added most to Amgen in Q2 2025, an estimated $1.45M increase.
- Virtus Investment Advisers's biggest Q2 2025 reduction was EOG Resources, cutting an estimated $1.23M.
- Virtus Investment Advisers fully exited Virtus Newfleet ABS/MBS ETF in Q2 2025, selling an estimated $32.2M.
- Virtus Investment Advisers's ten largest holdings make up 6.9% of its $296M portfolio in Q2 2025.
- Virtus Investment Advisers opened 39 new positions and closed 70 in Q2 2025.
- Virtus Investment Advisers's portfolio value fell 20% quarter-over-quarter to $296M.
Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.